US 11,702,481 B2
Anti-cub domain-containing protein 1 (CDCP1) antibodies, antibody drug conjugates, and methods of use thereof
Hong Ren, Brighton, MA (US); Scott Michael Lonning, Westford, MA (US); Nels Eric Pederson, Mansfield, MA (US); Klarisa Rikova, Reading, MA (US); Aleksandr Tkachev, Cambridge, MA (US); and Tinglei Gu, Andover, MA (US)
Assigned to Bluefin Biomedicine, Inc., Beverly, MA (US)
Appl. No. 16/469,197
Filed by Bluefin BioMedicine, Inc., Beverly, MA (US)
PCT Filed Dec. 15, 2017, PCT No. PCT/US2017/066661
§ 371(c)(1), (2) Date Jun. 13, 2019,
PCT Pub. No. WO2018/112334, PCT Pub. Date Jun. 21, 2018.
Claims priority of provisional application 62/588,516, filed on Nov. 20, 2017.
Claims priority of provisional application 62/488,445, filed on Apr. 21, 2017.
Claims priority of provisional application 62/435,509, filed on Dec. 16, 2016.
Prior Publication US 2020/0181281 A1, Jun. 11, 2020
Int. Cl. C07K 16/30 (2006.01); A61P 35/00 (2006.01); A61K 45/06 (2006.01); A61K 39/00 (2006.01); A61K 47/65 (2017.01); A61K 47/68 (2017.01)
CPC C07K 16/30 (2013.01) [A61K 47/65 (2017.08); A61K 47/6803 (2017.08); A61K 47/6849 (2017.08); A61P 35/00 (2018.01); A61K 45/06 (2013.01); A61K 2039/505 (2013.01)] 19 Claims
 
1. An antibody or antigen-binding fragment thereof that binds to CUB domain-containing protein 1 (CDCP1), wherein the antibody or antigen-binding fragment thereof comprises a heavy chain variable region comprising HCDR1, HCDR2, and HCDR3, and a light chain variable region comprising LCDR1, LCDR2, and LCDR3, wherein
HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences set forth in SEQ ID NOs: 155, 156, and 157 respectively, and LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences set forth in SEQ ID NOs: 158, 159, and 160, respectively.